Healthcare Industry News:  Diabetic Foot Ulcer 

Biopharmaceuticals Wound Care Personnel

 News Release - July 14, 2011

HealOr Names Dr. Michael L. Sabolinski, M.D. as New CEO

REHOVOT, Israel--(Healthcare Sales & Marketing Network)-- HealOr, a specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics for the treatment of chronic wounds such as Diabetic Foot Ulcer (DFU), announced today that its Board of Directors has named Dr. Michael L. Sabolinski, M.D. as the Company’s new CEO. Prior to the appointment, Dr. Sabolinski served as HealOr’s chief medical officer.

Dr. Sabolinski said, “I am honored to head HealOr’s talented team and look forward to working closely with the Company’s supportive Board of Directors. I have great confidence in our leading wound-care products and pipeline. Our main goal is to achieve FDA approval for HO/03/03, our flagship product for the treatment of Diabetic Foot Ulcers, which is currently being studied in a Phase II/III clinical trial in the U.S. and India.”

Dr. Sabolinski has more than 25 years of experience in wound-care research. He has worked as a scientist and a clinical investigator. He has also served as the sponsor of various clinical investigations of treatments for patients with acute and chronic wounds. Dr. Sabolinski is well known for his decade long career at Organogenesis, Inc. in Massachusetts, where he held several positions including president and chief executive officer. He successfully managed the team that secured two FDA approvals for a living skin substitute, thus pioneering the path for stem cell products and other cell therapies. In addition, he was instrumental in developing a partnership with Novartis Pharmaceuticals to globally market the Company's leading skin product. Dr. Sabolinski was also a partner and served as the chief medical officer at FoxKiser LLP.

Dr. Pini Orbach, a member of HealOr’s Board of Directors said, “The Company’s board unanimously selected Dr. Sabolinski based on his impressive and proven track record in the wound-care field, as well as his strong executive and personal skills. We strongly believe that HealOr will grow to be a successful pharmaceutical company and that Dr. Sabolinski’s leadership and experience will be instrumental in achieving our goals.”

About HealOr

Founded in 2002, HealOr is a privately owned, clinical-stage specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics to treat a variety of conditions such as acute and chronic wounds, psoriasis, and others. HealOr's research team, drawing on a deep understanding of the molecular mechanisms in skin tissue, has developed an entirely new treatment approach that revolutionizes wound healing and dermatological care. HealOr’s multi-Matrix approach goes beyond the treatment of a specific cell type or function, by also addressing multiple biochemical pathways and enhancing the skin’s overall intrinsic properties. HealOr is headquartered in Rehovot, Israel. For more information, please visit

Source: HealOr

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.